Not a single study
Story checked
Investigational Alopecia Areata Drug Shows Sustained Effect (opens in a new tab)
medscape.com · 2025-03-12
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Investigational Alopecia Areata Drug Shows Sustained Effect
medscape.com · 2025-03-12
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Also referencedpresented as the new finding
SIGNAL-AA
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedBempikibart, an experimental monoclonal antibody targeting the interleukin-7 receptor alpha and thymic stromal lymphopoietin pathway, appeared to provide major hair regrowth in alopecia areata with an effect that persisted after treatment was stopped.View evidenceHide evidence
As statedmajor hair regrowth; sustained after stopping
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedBrett King said the therapy's effect may be related to restoring T-cell homeostasis and could transform alopecia areata care if sustained clinical remission is confirmed in larger trials.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedIn the SIGNAL-AA phase 2a study, 33 patients with severe alopecia areata were randomized to bempikibart 200 mg subcutaneously every 2 weeks or placebo, with treatment continued for 24 weeks and additional monitoring for 12 weeks.View evidenceHide evidence
As stated33 patients; 24 weeks treatment; 12 weeks follow-up
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedAt 24 weeks, active-treatment groups had mean SALT reductions of about 17% in very severe alopecia areata and about 25% in severe alopecia areata, compared with less than 5% change for placebo.View evidenceHide evidence
As statedabout 17% and 25% versus <5% for placebo
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedThe article says benefit continued after treatment ended, with some leveling off but a trend toward lower SALT scores after dosing stopped; six patients had continued regrowth beyond week 36, and one patient reached SALT <10 by week 52.View evidenceHide evidence
As statedsix patients beyond week 36; one patient SALT <10 at 52 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedThe safety profile was described as encouraging, with almost all treatment-emergent adverse events mild to moderate and no grade 3 or higher adverse event considered drug-related.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedThe article also describes a separate phase 3 randomized trial of ivarmacitinib in 330 patients in China, where end-of-study SALT scores of 20 or less occurred in 34.9%, 40.6%, and 9.0% of patients assigned to 4 mg, 8 mg, and placebo, respectively.View evidenceHide evidence
As stated34.9%, 40.6%, and 9.0%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.
Journal of Inflammation Research · 2026 · PubMed, Europe PMC
Bempikibart shows its potential for hair regrowth in alopecia areata
Medicom Conference Report AAD 2025 · 2025 · Crossref
A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics.
2026 · Europe PMC
Alopecia Areata and Alopecia Areata Incognita
Alopecia · 2019 · Crossref
Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges - A Narrative Review.
2026 · Europe PMC
And 10 more candidates considered.